Abstract:The final, formatted version of the article will be published soon. You have multiple emails registered with Frontiers: Please enter your email address: If you already have an account, please login You don't have a Frontiers account ? You can register here Cellular mesenchymal-epithelial transition factor (c-MET), or hepatocyte growth factor receptor (HGFR), is a critical tyrosine kinase receptor in various solid tumors, including lung, breast, and liver cancers. This review examines the potential of integrating c-MET inhibition with immunotherapy to revolutionize cancer treatment. Moreover, the co-expression of c-MET and PD-L1 in tumors, such as hepatocellular carcinoma, underscores the prognostic significance and resistance to therapies. HGF from cancer-associated fibroblasts (CAFs) and mesenchymal stromal cells (MSCs) activates c-MET signaling in tumor cells and myeloid-derived suppressive cells (MDSCs), leading to metabolic reprogramming and secretion of Indoleamine 2,3-dioxygenase (IDO), glutaminase (GLS), and arginase 1 (ARG1). This depletes immune cells by limiting essential amino acids. Tumor-MDSC collaboration induces immune suppression, offering targets for intervention to enhance c-MET-targeted immunotherapy. Furthermore, cisplatin-induced chemoresistance, mediated by increased HGF levels and subsequent PD-L1 expression, can also counteract c-MET inhibitors, restoring anticancer immunity. This combined approach can significantly improve clinical outcomes by addressing immune evasion and enhancing anti-tumor immunity. On the other hand, the emerging field of c-MET-specific chimeric antigen receptor (CAR) cell therapies, including CAR-T and CAR-NK cells, which offers a precise approach to treating c-MET+ malignancies and antibody-based drugs targeting c-MET, including monoclonal antibodies, bispecific antibodies, and antibody-drug conjugates, as delivery systems and anti-c-MET agents for c-MET+ cancer cells, are also discussed in the present review. By exploring the impact of c-MET inhibition on the accumulation and transition of tumor-associated neutrophils, macrophages, regulatory T cells (Tregs), other T cells, and NK cells, the significant clinical implications of c-MET targeting in cancer therapy are highlighted. Combined with conventional treatments, immunotherapies show promise in managing cancer overexpressing c-MET. The review also investigates the crosstalk between c-MET and TGF-β pathways and the galectin family, contributing to immune evasion and cancer cell invasiveness. Despite the challenges and variability in efficacy across different cancer subtypes, continued research into the molecular mechanisms and the development of innovative therapeutic strategies will be crucial.

Nmet, A New Target in Recurrent Cancer

Potential Therapeutics Specific to C-Met/ron Receptor Tyrosine Kinases for Molecular Targeting in Cancer Therapy.

MicroRNAs and Long Non-coding RNAs in c-Met-Regulated Cancers

Progress and Challenge in Development of Biotherapeutics Targeting MET Receptor for Treatment of Advanced Cancer.

Cmet As A Potential Therapeutic Target In Gastric Cancer

Oncogenic mechanism-based pharmaceutical validation of therapeutics targeting MET receptor tyrosine kinase

Targeting MET in NSCLC: An Ever-Expanding Territory

Aberrant RON and MET Co-overexpression As Novel Prognostic Biomarkers of Shortened Patient Survival and Therapeutic Targets of Tyrosine Kinase Inhibitors in Pancreatic Cancer.

The MET Oncogene: An Update on Targeting Strategies

HNRNPA2B1 as a potential therapeutic target for thymic epithelial tumor recurrence: An integrative network analysis

MET Exon 14 Skipping Mutation Drives Cancer Progression and Recurrence Via Activation of SMAD2 Signalling

MET alterations and therapeutic strategies in non-small cell lung cancer

Targeting MET in Non-Small Cell Lung Cancer: an Ever-Expanding Territory

Known and novel roles of the MET oncogene in cancer: a coherent approach to targeted therapy

MET Oncogene Targeting for Cancer Immunotherapy

Roles of MET in human cancer

CircMET promotes tumor proliferation by enhancing CDKN2A mRNA decay and upregulating SMAD3

Targeted Therapy Approaches for MET Abnormalities in Non-Small Cell Lung Cancer

MET Kinase Domain Rearrangements Across 10 Cancer Types.

c-MET and the immunological landscape of cancer: novel therapeutic strategies for enhanced anti-tumor immunity

Unraveling the Significance of MET Focal Amplification in Lung Cancer: Integrative NGS, FISH, and IHC Investigation